← All verdicts
Verdict

Valuation N/A

Every analyzed stock in Valuation N/A — 479 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Valuation N/A" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
CMIIW
Inflection Point Acquisition Corp. VII
Valuation N/A
Technology
Price$0.72
Model IV—
P/IV—
Limited data — see page
CNCKW
Coincheck Group N.V.
Valuation N/A
Financial Services Risk 31 · Moderate
Price$0.31
Model IV—
P/IV—
Market implies -50.0%/yr vs model +37.6% · below model
COCHW
Envoy Medical, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.05
Model IV—
P/IV—
Market implies +25.0%/yr vs model +15.0% · above model
COLAU
Columbus Acquisition Corp/Cayman Islands
Valuation N/A
Financial Services Risk 43 · Elevated
Price$10.44
Model IV—
P/IV—
Limited data — see page
COOTW
Australian Oilseeds Holdings Ltd
Valuation N/A
Consumer Defensive Risk 46 · Elevated
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr vs model +17.6% · below model
CORZW
Core Scientific, Inc./tx
Valuation N/A
Financial Services Risk 25 · Moderate
Price$11.22
Model IV—
P/IV—
Market implies +43.8%/yr vs model +2.0% · above model
CRACU
Crown Reserve Acquisition Corp. I
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
CRACW
Crown Reserve Acquisition Corp. I
Valuation N/A
Financial Services
Price$0.05
Model IV—
P/IV—
Limited data — see page
CRANU
Crane Harbor Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.34
Model IV—
P/IV—
Limited data — see page
CRAQU
Cal Redwood Acquisition Corp.
Valuation N/A
Financial Services
Price$10.49
Model IV—
P/IV—
Limited data — see page
CSHRW
CoinShares PLC
Valuation N/A
Financial Services Risk 54 · Elevated
Price$1.13
Model IV—
P/IV—
Limited data — see page
CTAAU
Clearthink 1 Acquisition Corp.
Valuation N/A
Financial Services Risk 33 · Moderate
Price$10.12
Model IV—
P/IV—
Limited data — see page
CTRA
CTRA
Valuation N/A
Price$32.56
Model IV—
P/IV—
Limited data — see page
CUBWW
Lionheart Holdings
Valuation N/A
Financial Services
Price$0.25
Model IV—
P/IV—
Limited data — see page
CXIIU
Churchill Capital Corp XII
Valuation N/A
Financial Services
Price$11.14
Model IV—
P/IV—
Limited data — see page
CYCUW
Cycurion, Inc.
Valuation N/A
Technology Risk 33 · Moderate
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
CYDY
CytoDyn Inc.
Valuation N/A
Healthcare Risk 68 · High
Price$0.20
Model IV—
P/IV—
Market implies +93.8%/yr vs model +15.0% · above model
DAAQU
Digital Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$11.76
Model IV—
P/IV—
Limited data — see page
DAAQW
Digital Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$0.14
Model IV—
P/IV—
Limited data — see page
DAICW
CID Holdco, Inc.
Valuation N/A
Technology Risk 41 · Elevated
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
DAVEW
Dave Inc./DE
Valuation N/A
Financial Services Risk 43 · Elevated
Price$1.87
Model IV—
P/IV—
Market implies -50.0%/yr
DBCAU
D. Boral Acquisition I Corp.
Valuation N/A
Financial Services Risk 38 · Moderate
Price$10.40
Model IV—
P/IV—
Limited data — see page
DBCAW
D. Boral Acquisition I Corp.
Valuation N/A
Financial Services
Price$0.37
Model IV—
P/IV—
Limited data — see page
DFLIW
Dragonfly Energy Holdings Corp.
Valuation N/A
Technology Risk 36 · Moderate
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr
DFNSW
T3 Defense Inc.
Valuation N/A
Industrials Risk 31 · Moderate
Price$0.07
Model IV—
P/IV—
Market implies -24.4%/yr
DFSCW
DEFSEC Technologies Inc.
Valuation N/A
Technology Risk 31 · Moderate
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr
DJTWW
Trump Media & Technology Group Corp.
Valuation N/A
Technology Risk 51 · Elevated
Price$4.81
Model IV—
P/IV—
Market implies +81.3%/yr
DMAAU
Drugs Made In America Acquisition Corp.
Valuation N/A
Financial Services Risk 46 · Elevated
Price$10.79
Model IV—
P/IV—
Limited data — see page
DMIIU
Drugs Made In America Acquisition II Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.20
Model IV—
P/IV—
Limited data — see page
DNMXU
Dynamix Corp III
Valuation N/A
Financial Services Risk 40 · Elevated
Price$10.16
Model IV—
P/IV—
Limited data — see page
DNMXW
Dynamix Corp III
Valuation N/A
Financial Services
Price$0.23
Model IV—
P/IV—
Limited data — see page
DRDBU
Roman DBDR Acquisition Corp. II
Valuation N/A
Financial Services Risk 38 · Moderate
Price$10.72
Model IV—
P/IV—
Limited data — see page
DRDBW
Roman DBDR Acquisition Corp. II
Valuation N/A
Financial Services
Price$0.17
Model IV—
P/IV—
Limited data — see page
DRMAW
DRMAW
Valuation N/A
Risk 40 · Elevated
Price$0.00
Model IV—
P/IV—
Limited data — see page
DRTSW
Alpha Tau Medical Ltd.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.84
Model IV—
P/IV—
Limited data — see page
DSACU
Daedalus Special Acquisition Corp.
Valuation N/A
Financial Services
Price$10.30
Model IV—
P/IV—
Limited data — see page
DSACW
Daedalus Special Acquisition Corp.
Valuation N/A
Financial Services
Price$0.80
Model IV—
P/IV—
Limited data — see page
DTSQU
DT Cloud Star Acquisition Corp
Valuation N/A
Financial Services Risk 42 · Elevated
Price$11.49
Model IV—
P/IV—
Limited data — see page
DUKRW
DUKE Robotics Corp.
Valuation N/A
Industrials Risk 45 · Elevated
Price$1.33
Model IV—
P/IV—
Market implies +39.3%/yr
DYNCU
Dynamix Corp
Valuation N/A
Financial Services
Price$11.21
Model IV—
P/IV—
Limited data — see page
DYNCW
Dynamix Corp
Valuation N/A
Financial Services
Price$0.12
Model IV—
P/IV—
Limited data — see page
DYORU
Insight Digital Partners II
Valuation N/A
Financial Services Risk 40 · Elevated
Price$10.22
Model IV—
P/IV—
Limited data — see page
DYORW
Insight Digital Partners II
Valuation N/A
Financial Services
Price$0.20
Model IV—
P/IV—
Limited data — see page
EC
ECOPETROL S.A.
Valuation N/A
Energy Risk 47 · Elevated
Price$18.26
Model IV—
P/IV—
Limited data — see page
ECXWW
ECARX Holdings Inc.
Valuation N/A
Technology Risk 55 · Elevated
Price$0.03
Model IV—
P/IV—
Market implies -50.0%/yr
EGHAU
EGH Acquisition Corp.
Valuation N/A
Financial Services
Price$10.66
Model IV—
P/IV—
Limited data — see page
ELVR
Elevra Lithium Ltd
Valuation N/A
Basic Materials Risk 59 · Elevated
Price$50.82
Model IV—
P/IV—
Market implies +95.8%/yr
ENB
ENBRIDGE INC
Valuation N/A
Energy Risk 33 · Moderate
Price$48.16
Model IV—
P/IV—
Market implies +83.9%/yr vs model +4.0% · above model
ENGNW
enGene Therapeutics Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.23
Model IV—
P/IV—
Limited data — see page
EPOW
E-Power Inc.
Valuation N/A
Technology Risk 41 · Elevated
Price$0.27
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
ERNAW
Ernexa Therapeutics Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$0.04
Model IV—
P/IV—
Market implies -13.1%/yr
ESLAW
Estrella Immunopharma, Inc.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$0.07
Model IV—
P/IV—
Limited data — see page
EUDAW
EUDA Health Holdings Ltd
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.04
Model IV—
P/IV—
Market implies -50.0%/yr
EURKU
Eureka Acquisition Corp
Valuation N/A
Industrials Risk 38 · Moderate
Price$11.72
Model IV—
P/IV—
Limited data — see page
EVGOW
EVGOW
Valuation N/A
Risk 49 · Elevated
Price$0.01
Model IV—
P/IV—
Limited data — see page
EVI
EVI INDUSTRIES, INC.
Valuation N/A
Consumer Cyclical Risk 57 · Elevated
Price$15.90
Model IV—
P/IV—
Market implies +135.0%/yr vs model +9.6% · above model
EVLVW
EVLVW
Valuation N/A
Risk 49 · Elevated
Price$0.08
Model IV—
P/IV—
Limited data — see page
EVOXU
Evolution Global Acquisition Corp
Valuation N/A
Financial Services Risk 40 · Elevated
Price$10.28
Model IV—
P/IV—
Limited data — see page
EVOXW
Evolution Global Acquisition Corp
Valuation N/A
Financial Services
Price$0.36
Model IV—
P/IV—
Limited data — see page
EXYNW
Exyn Technologies, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$0.34
Model IV—
P/IV—
Limited data — see page